hydroxychloroquine for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. antiviral and associated therapy
vs. azithromycin
vs. control
vs. placebo
vs. standard of care
vs. Vitamins
vs. vitamin C

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

IRCT20150808023559N20, 0 IRCT20150808023559N2

hydroxychloroquine vs. hydroxychloroquine

COVID 19 all comers

NCT04376814-Group A, 2020 NCT04376814

hydroxychloroquine vs. hydroxychloroquine

COVID 19 all comers

IRCT20150808023559N20, 0 IRCT20150808023559N2

hydroxychloroquine vs. lopinavir/ritonavir

COVID 19 all comers

NCT04376814-Group A, 2020 NCT04376814

hydroxychloroquine vs. lopinavir/ritonavir

COVID 19 all comers

ChiCTR2000030054-HCQ (Chen), 2020 ChiCTR2000030054

hydroxychloroquine vs. standard of care

COVID 19 all comers

NOR-Solidarity (hydroxychloroquine), 2021 NCT04321616

hydroxychloroquine vs. standard of care

COVID 19 all comers

Gautret et al., 2020

hydroxychloroquine vs. standard of care

COVID 19 all comers

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open